Background and objectives. Acute kidney injury (AKI) is common in critically ill patients and is associated with a high mortality rate. Pre-renal azotemia, suggested by a high blood urea nitrogen to serum creatinine (BUN:Cr) ratio (BCR), has traditionally been associated with a better prognosis than other forms of AKI. Whether this pertains to critically ill patients is unknown.
Introduction
Acute kidney injury (AKI) is common among hospitalized patients [1] and most common among critically ill patients [2, 3] . AKI is strongly associated with adverse clinical outcomes, including mortality [2, [4] [5] [6] [7] [8] [9] [10] [11] .
The differential diagnosis of AKI classically includes pre-renal, renal and post-renal causes [12] . Pre-renal azotemia results from a reduction in glomerular filtration rate (GFR) in response to a degree of renal hypoperfusion that exceeds the autoregulatory capacity of the kidney [12] . In pre-renal azotemia, the structural integrity of the kidney is assumed to be unscathed since resolution of the azotemia rapidly follows restoration of normal renal perfusion.
Urea and creatinine both undergo glomerular filtration. Unlike creatinine, however, urea undergoes tubular reabsorption. Therefore, in states of renal hypoperfusion with intact tubular function and augmented tubular reabsorption, the blood urea nitrogen (BUN) concentration tends to rise out of proportion to the serum creatinine concentration (S Cr ) [13] . This is thought to account for the observation of a high BUN:creatinine ratio (BCR) in patients with pre-renal azotemia. A recent study, for example, showed an average BCR of 26-30 in patients with pre-renal azotemia compared with a BCR of 11 in patients with intrinsic renal failure [14] .
Consistent with its proposed pathogenesis, pre-renal azotemia is associated with better clinical outcomes than intrinsic renal failure [15] . One study showed that patients with pre-renal azotemia had a mortality rate of only 7% compared with 55% in patients with intrinsic renal failure [16] , and Liaño and Pascual [17] demonstrated a similarly lower mortality in hospitalized patients with pre-renal azotemia compared with those with acute tubular necrosis.
Therefore, a diagnosis of pre-renal azotemia based on a high BCR would seem to offer clinicians some reassurance about the patient's prognosis. But such reassurance may be unfounded, particularly in critically ill patients. Patients with pre-renal azotemia tend to have a high BCR, but a high BCR does not necessarily imply pre-renal azotemia. The BUN may increase not just because of tubular reabsorption of urea but due to an increase in urea generation rate (from exogenous or endogenous protein catabolism). Critically ill patients are prone to accelerated protein catabolism, which may cloud the implications of what might otherwise appear to be a 'benign' high BCR. Moreover, as a ratio, the BCR may rise from a low rate of creatinine generation (from low muscle mass). One study reported a very high BUN (average BCR of 36) in a small group of critically ill patients who had high protein catabolism and low muscle mass. Fifty-eight percent of the patients died but in that study, no comparison was made with outcomes in patients with a low BCR [18] .
In this study, we aimed to clarify the prognostic implications of a high BCR in critically ill patients. We hypothesized that a BCR >20 is not associated with lower mortality or reduced need for renal replacement therapy (RRT) in critically ill patients.
Materials and methods

Study design
We conducted a retrospective, single center observational study of patients of critically ill patients. The study was approved by the Institutional Review Board of Cooper University Hospital.
Record selection
We included patients aged at least 18 years, admitted to the mixed medical-surgical intensive care unit (ICU) or the trauma ICU at Cooper University Hospital, a 550-bed tertiary referral center. For purposes of the study, we refer to the two ICUs collectively as the ICU. We excluded patients who were receiving RRT before admission to the ICU.
We analyzed patient records in two independent sets: (i The derivation cohort included patients who survived >24 h in the ICU and had at least two measurements of S Cr . The derivation cohort was used to identify a S Cr cut-point defining a range of values predictive of AKI. This S Cr cut-point was validated in the second cohort as a predictor of mortality and RRT.
If patients were admitted to the ICU more than once during the study period, only the last admission was considered for analysis.
Data collection
Patients in both cohorts were identified from the Project ImpactÒ (PI) database [19] , which houses prospectively collected clinical information about all critically ill patients in our institution.
For the derivation cohort, we retrieved additional laboratory data from the electronic medical information system. We recorded the first simultaneous BUN and S Cr of the day for each of the first three calendar days of their ICU stay. For the validation cohort, we recorded only the highest BUN and S Cr during the first 24 h of their ICU stay.
Demographic information, length of stay, complications while in hospital, APACHE II score, use of mechanical ventilation and vasopressors and use of RRT were recorded prospectively and entered into the PI database. In addition, the following comorbid conditions were recorded and entered prospectively: chronic kidney disease (CKD), hypertension (HTN), congestive heart failure (CHF) and chronic obstructive pulmonary disease (COPD).
We defined AKI as any change (increase or decrease [20] ) in S Cr of 0.3 mg/dL during the first 2 days [21] .
Data analysis
Outcomes of interest were new in-hospital RRT and in-hospital mortality. We tested proportion differences within cohorts for significance by Pearson chi-square or Mann-Whitney U-tests. We analyzed correlations using Spearman coefficient. To identify S Cr ranges on the day of ICU admission (S Cr1 ) most predictive of ARF status, we applied a chi-square automatic interaction detection (CHAID) recursive segmentation model [22] . The CHAID algorithm enabled up to 20 cut-points to be defined for continuous Fallacy of the BCRS Cr values on Day 1 (S Cr1 ) with Bonferroni adjustment of recursive significance tests used to determine distinct S Cr1 values minimizing withinrange and maximizing between-range variation.
A stepwise multivariable logistic regression (backward elimination based on likelihood ratio) was used to adjust mortality and new RRT associations with BCR >20 and S Cr1 for the following risk factors: age, gender (female), race (Caucasian versus other), APACHE II score, use of vasopressors, use of mechanical ventilation, diabetes mellitus, CKD, CHF, HTN and COPD.
We performed a Kaplan-Meier survival analysis for new RRT and inhospital mortality separately. In the survival analysis, the events (death within 30 days and new RRT within 30 days) were analyzed using a logrank test (Mantel-Cox).
We divided the distribution of BCR and S Cr in the validation cohort by decile (10 equal groups) and compared mortality in all groups with that in the index decile (that with the lowest mortality rate). SPSS version 13.0 (Chicago, IL) was used for all analyses.
Results
Derivation cohort
During this study period, 1240 patients were admitted to the ICU. Of these, 230 records were excluded: 29 because they had fewer than two S Cr measurements; 180 due to repeat admissions; 20 because of missing data on risk factors and 1 patient on RRT before admission to the ICU. A total of 1010 patients are included in the derivation cohort ( Figure 1a ). Recursive segmentation (CHAID) analysis revealed that a S Cr on the day of ICU admission (S Cr1 ) of at least 1.0 mg/dL was associated with increased group homogeneity with respect to the development of AKI; that is, patients with S Cr1 1.0 mg/dL were significantly more likely to develop AKI than patients with S Cr1 <1.0 mg/dL [odds ratio (OR) 4.8 (3.6-6.3)], P < 0.001]. Table 1 shows the baseline data for the derivation cohort. The BCR was >20 in 518 patients (51%). These patients were more likely to be older, female, white and have a higher APACHE II score. In addition, they had a higher prevalence of diabetes mellitus, HTN and COPD. The group of patients with a BCR >20 had both a higher average BUN and a lower average S Cr on admission to the ICU.
Clinical outcomes for the derivation cohort are shown in Table 2 . Patients with a BCR >20, in the group as a whole and in and both 'high-risk' subgroups (AKI and S Cr1 >1.0 mg/dL), had a higher mortality, before and after adjusting for differences between groups. Patients in the group as a whole with a BCR >20 were less likely to undergo RRT [unadjusted OR 0.27 (0.1-0.74), P ¼ 0.008 and adjusted OR 0.3 (0.1-0.9), P ¼ 0.047]. The same tendency was observed in patients with S Cr1 >1.0 mg/dL and AKI, although the results did not achieve statistical significance.
Validation cohort
There were 12 746 admissions to the ICU during this study period, of which 11 416 represented unique patients. We excluded 438 records because the patients were receiving RRT before admission to the ICU and 750 because of missing data, leaving 10 228 records in the validation cohort (Figure 1b) . Of those, 4296 (42%) had a BCR >20. Baseline characteristics of this cohort, by BCR cut-point, are shown in Table 3 .
Again, patients with a BCR >20 were more likely to be female, older and white, and to have a higher APACHE II score. This larger cohort revealed associations of a BCR >20 with a variety of underlying chronic conditions, including diabetes mellitus, HTN, CHF and COPD. The use of vasopressors and mechanical ventilation was more common among patients with a BCR >20. Once again, the group with a BCR >20 had both a higher average BUN and a lower average S Cr . We found significant correlations between BUN and APACHE II score (P ¼ 0.19, P < 0.001) and age (P ¼ 0.40, P < 0.001).
Mortality in the validation cohort as a whole was 13.5, and 2.4% of the cohort underwent RRT.
We applied the S Cr1 cut-point of 1.0 mg/dL-found in the derivation cohort to increase the likelihood of AKI-to define a high-risk subgroup in the validation cohort. We identified 4201 in this high-risk subgroup. A BCR >20 in the cohort as a whole, and in the high-risk subgroup, was associated with increased mortality and lower likelihood of RRT, both before and after adjustment (Table 4 ). We analyzed mortality across deciles defined by BCR in the group as a whole. This revealed a J-shaped relationship between BCR and mortality ( Figure 2) , with the lowest mortality (9.7%) seen in Decile 3 (BCR 13.75-15.5). Dividing the cohort into deciles defined by S Cr revealed a similar J-shaped relationship with mortality ( Figure 3) , with the lowest mortality (7%) seen in Decile 3 (S Cr 0.6-0.7).
a. Acquisition of the derivation cohort
The time to death and time to RRT are represented by Kaplan-Meier survival curves (Figures 4 and Figure 5 , respectively). The log-rank test showed significant differences between the BCR groups for both in-hospital mortality within 30 days {hazard ratio 1.5 [95% confidence interval (CI)], 1.3-1.6} and new RRT within 30 days [hazard ratio 0.5 (95% CI, 0.4-0.7)] (both P < 0.001). The curve for cumulative incidence of RRT flattens substantially~15 days, whereas that for survival shows a linear decline over time. The median [interquartile range, IQR] time to death was significantly shorter in the BCR >20 group than in the BCR <20 group (7 [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] days versus10 [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] days, P < 0.001). Conversely, the median [IQR] time to dialysis was significantly longer in the BCR >20 group than in the BCR <20 group (6 [1.5-10] days versus 4 [1-14] days, P < 0.001).
Discussion
We examined mortality and new RRT in critically ill patients stratified by BCR. BCR >20 has long been viewed as indicative of pre-renal azotemia, which is generally thought to have a more benign prognosis than other causes of AKI [15] . Contrary to this conventional wisdom, however, results from this study of critically ill patients show that a BCR >20 is associated with higher mortality than in patients with a low BCR. How can we explain this paradoxical observation?
The patients in our study with a BCR >20 had both a higher average BUN and a lower average S Cr than patients with a BCR 20. To begin to understand the relationship between BCR and clinical outcomes in our study, we will first examine the factors that tend to raise the BUN, to see if those factors are associated with the higher mortality.
Classically, a high BCR in AKI implies pre-renal azotemia based on the pathophysiologic construct of intact tubular function and enhanced urea reabsorption, in the setting of renal hypoperfusion [13] . This conception might be valid if other conditions affecting the BUN were held constant. Such is not the case in critically ill patients, however. Critical illness is associated with increased protein catabolism and increased urea generation rate [23] . One might logically assume that the severity of illness correlates with the intensity of protein catabolism. Furthermore, advancing age is associated with resistance to protein anabolism, perhaps by way of insulin resistance [24] . Patients with a BCR >20 in our study were older, and their APACHE II score was higher than patients in the low BCR group. Both APACHE II (our data show a correlation between APACHE II score and BUN, but this is confounded by the inclusion of another measure of renal function, S Cr , in the calculation of the APACHE II) and age correlate significantly with BUN in our population. Thus, we suspect that at least part of the reason for the high BCR in this critically ill population is a higher protein catabolic rate. The very factors that lead to the high protein catabolic rate-severity of illness and age-are clearly associated with increased mortality in critically ill patients [25] [26] [27] .
BCR being a ratio, the denominator, S Cr , must be considered for its possible contribution to the high BCR and to mortality. At any given GFR, S Cr is a function of muscle turnover, itself a function of muscle mass. Muscle mass declines steadily with age, and at any age, women tend to have less muscle mass than men [28] . Furthermore, whites tend to have less muscle mass and generate less creatinine than blacks [29] . Patients in our study with a BCR >20 had a lower average S Cr than patients in the lower BCR group. They were significantly older. Moreover, the high BCR group had a significantly higher proportion of whites and women. These factors could account for the lower S Cr .
To what extent might these same factors track with mortality? Clearly, age is associated with increased mortality among critically ill patients [30] [31] [32] . Female gender was also associated with higher mortality rate in a large study of critically ill patients [33] . Indeed, creatinine generation rate has been inversely associated with severity of illness in patients with ARF [34, 35] .
Thus, both the high BUN and lower S Cr are explicable by factors other than a 'pre-renal' state, and those factors are associated with increased mortality.
Our findings are concordant with those of other trials. A retrospective study of 11 291 critically ill patients showed that low baseline serum creatinine was independently associated with increased mortality [36] . Analysis of data from the BEST Kidney study showed that patients with sepsisassociated AKI who had impaired pre-morbid kidney function (and thus a higher baseline SC r ) had a trend towards lower mortality [37] .
We also found that patients with a high BCR were less likely to undergo RRT than patients with a low BCR. The reasons for this are not obvious, mainly because the study design does not allow us to discriminate between, on one hand, RRT that was indicated but withheld and, on the other hand, unnecessary RRT. The Kaplan-Meier survival curve analyses of time to death and time to RRT suggest that there was ample opportunity to initiate RRT before death. It is interesting to speculate that the high BCR may have led the clinicians to think the AKI was pre-renal and would resolve with restoration of renal perfusion. This, in turn, may have encouraged them to withhold RRT. Insofar, as the relatively low S Cr in this group may have led the clinicians to underestimate the severity of the AKI, it might have had an effect similar to the high BCR. The role of gender in regard to initiating RRT is unknown, but somewhat disturbing to contemplate. A large study of critically ill patients showed that women are less likely to undergo technical or invasive procedures than men with identical APACHE II scores and yet had a higher mortality [33] . (In that study, however, there was no disparity in the use of hemodialysis [33] .) The detailed chart review that would have been required to support or refute such speculation is beyond the scope of this study.
If the BCR is a poor indicator of pre-renal azotemia in critically ill patients, as it appears to be, is there a better method to diagnose pre-renal azotemia in this population? The answer to this question is not readily apparent. Low urinary sodium concentration and a low fractional excretion of sodium, commonly accepted indices of renal hypoperfusion, are unreliably associated with pre-renal azotemia and, indeed, are commonly reported in sepsis-associated AKI [38, 39] . Physical assessment of volume status may be equally unreliable [40] , especially in critically ill patients where the usual indices (such as edema and vital signs) are frequently misleading rendering such an endeavor quite challenging. The surest way to diagnose prerenal azotemia is to observe prompt improvement in renal function with restoration of normal hemodynamics, which often requires fluid administration to a patient thought to be volume depleted. Even this is frought with uncertainty, however, since failure of the renal function to improve could reflect either an inadequate 'fluid challenge' or volumeunresponsive kidney failure. Thus, the BCR appears to be another of a number of unreliable tools for the diagnostic evaluation of a patient with AKI.
Interpretation of our results is limited by the fact that we did not analyze chart-level information. This is particularly germane to the issue of RRT, as discussed above. The use of recursive segmentation (CHAID) analysis to define a highrisk subgroup based on the initial S Cr alone might be judged overly simplistic. It did, however, define a subgroup with roughly 5-fold likelihood of developing AKI, and it allowed us to construct a similar high-risk subgroup in the larger validation cohort. Fractional excretion of sodium (FENa) was not recorded, but we believe this would shed little light on our results, for reasons we discussed above [38, 39] . Underlying CKD could influence the propensity for AKI and may influence its outcome. We did not estimate GFR in this population because we lacked a reliable stable 'baseline' S Cr . All patients in all groups, however, were susceptible to this limitation. Lastly, in the validation cohort, although the recorded BUN and creatinine were each the highest in the first 24 h of the ICU stay, they were not necessarily drawn simultaneously. While we are unable to estimate the impact of this possible time discrepancy on the BCR, it applied to all patients in the validation cohort.
In conclusion, contrary to the conventional wisdom that associates BCR >20 with pre-renal azotemia and a more benign prognosis, we found a high BCR to be associated with increased mortality in critically ill patients. We also found that a high BCR was associated with a lower likelihood of undergoing RRT. Based on these findings, we recommend abandoning the BCR as an adjunct to the diagnosis of pre-renal azotemia in critically ill patients.
